Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 706321 in Healthy Male Subjects (an Open-label, Two-period Fixed Sequence Design Study)
Phase: PHASE1
Conditions: Healthy
Sponsor: Boehringer Ingelheim

001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Clinical Trial Protocol
TITLE PAGE
Document Number:
c32737758-02
EudraCT No.
2020-004388-22
BI Trial No.
1425-0010
BI Investigational
Medicinal Product
BI 706321
Title
Effect of itraconazole on the pharmacokinetics of a single oral 
dose of BI 706321 in healthy male subjects (an open-label, two-
period fixed sequence design study)
Lay Title
A study in healthy men to test how itraconazole influences the 
amount of BI 706321 in the blood
Clinical Phase
I
Clinical Trial Leader
Phone:
Fax: 
Principal 
Investigator
Phone: 
Fax: 
Status
Final Protocol (Revised Protocol (based on global amendment 1))
Version and Date
Version: 2.0
Date: 01 February 2021
Page 1 of 60
Proprietary confidential information
© 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 2 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
CLINICAL TRIAL PROTOCOL SYNOPSIS
Company name
Boehringer Ingelheim
Protocol date
02 November 2020
Revision date
01 February 2021
BI trial number
1425-0010
Title of trial
Effect of itraconazole on the pharmacokinetics of a single oral dose of BI 706321 in 
healthy male subjects (an open-label, two-period fixed sequence design study)
Principal Investigator:
Trial site
Clinical phase
I
Trial rationale
Based on in vitro data, CYP3A4 and P-gp are involved in metabolism and transport 
of BI 706321, respectively. It is therefore necessary to explore the relative 
bioavailability of BI 706321 in plasma when given alone versus when given 
together with a strong CYP3A4 and P-gp inhibitor.
Trial objective
To investigate the pharmacokinetics of a single oral dose of BI 706321 when given 
alone (treatment R) or in combination with itraconazole (treatment T)
Trial design
Open-label, two-treatment, two-period fixed sequence design
Trial endpoints:
Primary endpoints: AUC0-and Cmax of BI 706321 in plasma
Secondary endpoints: AUC0-tz of BI 706321 in plasma
Number of subjects 
total entered
14
each treatment
14
Diagnosis
Not applicable
Main criteria
for inclusion
Healthy male subjects, age of 18 to 50 years (inclusive), body mass index (BMI) of 
18.5 to 29.9 kg/m2 (inclusive)
Test product 1
BI 706321 tablet formulation 
 tablet strength)
dose
as single dose
mode of admin.
Oral with 240 mL of water after an overnight fast of at least 10 h

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 3 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Test product 2
Itraconazole oral solution (Sempera® Liquid 10 mg/mL)
dose
200 mg once daily (q.d.)
mode of admin.
Oral with 240 mL of water after an overnight fast of at least 9 h
Duration of treatment
Treatment R (BI 706321 alone):
Single dose of 
 BI 706321 (Day 1)
Treatment T (itraconazole + BI 706321):
14 days of itraconazole treatment (200 mg itraconazole once daily from Day -3 to 
Day 11) combined with a single dose of 
 BI 706321 on the fourth day of the 
itraconazole treatment (Day 1, 1 h after the itraconazole administration)
Wash-out period:
Administrations of BI 706321 will be separated by a wash-out phase of at least 14
days.
Statistical methods
Extent of drug-drug-interaction will be estimated by the ratios of the geometric 
means (test/reference) for the primary and secondary endpoints. Additionally, their 
two-sided 90% confidence intervals (CIs) will be provided. This method 
corresponds to the two one-sided t-test procedure, each at a 5% significance level. 
Since the main focus is on estimation and not testing, a formal hypothesis test and 
associated acceptance range are not specified. The statistical model will be an 
analysis of variance (ANOVA) on the logarithmic scale including effects for 
‘subject’ and ‘treatment’. CIs will be calculated based on the residual error from the 
ANOVA.
Descriptive statistics will be calculated for all endpoints.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 4 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
FLOW CHART
Period
Visit
Day
Planned time (relative to 
drug administration) 
[h:min]
Approximate clock time  
of actual day [h:min]
Event and comment
Safety laboratory5
PK blood, BI 706321
12-lead ECG
Vital signs (Body 
temperature, BP, PR)
Questioning for AEs and 
concomitant therapy 7
SCR
1
-21 to -3
Screening (SCR)1
xA
x
x
Period 1/ Treatment R (BI 706321 alone)8
2
-3 to -1
-73:00
08:00
Ambulatory visit
xB
x
1
-3:00
06:00
Admission to trial site2
x2,3
x2
x2
x2
x2
0:00
09:00
BI 706321 administration
0:30
09:30
x
1:00
10:00
x
2:00
11:00
240 mL fluid intake
x
3:00
12:00
x
4:00
13:00
240 mL fluid intake, thereafter lunch4
x
x
x
x
5:00
14:00
x
6:00
15:00
x
7:00
16:00
Snack (voluntary)4
x
8:00
17:00
x
10:00
19:00
Dinner4
x
12:00
21:00
x
x 
2
24:00
09:00
Breakfast (voluntary)4, 
discharge from trial site
xB
x
x
x
x
34:00
19:00
Ambulatory visit
x
x
3
46:00
07:00
Ambulatory visit
x
x
4
70:00
07:00
Ambulatory visit
x
x
5
94:00
07:00
Ambulatory visit
x
x
6
118:00
07:00
Ambulatory visit
x
x
7
142:00
07:00
Ambulatory visit
xB
x
x
8
166:00
07:00
Ambulatory visit
x
x
9
190:00
07:00
Ambulatory visit
x
x
1.
Subject must be informed and written informed consent obtained prior to starting any screening procedures. Screening 
procedures include physical examination, check of vital signs, ECG, safety laboratory (including drug screening), 
demographics (including determination of body height and weight, smoking status and alcohol history), relevant 
medical history, concomitant therapy and review of inclusion/exclusion criteria. 
2.
The time is approximate; the procedure is to be performed and completed within the 3 h prior to drug administration.
3.
Urine drug screening and alcohol breath test
4.
If several actions are indicated at the same time, the intake of meals will be the last action.
5.
Letters A, B, C, and D define different sets of safety laboratory examinations (for details refer to Table 5.2.3: 1)
6.
At the end of trial visit the EoTrial examination includes physical examination, vital signs, ECG, safety laboratory, 
recording of AEs and concomitant therapies. 
7.
AEs and concomitant therapies will be recorded throughout the trial, but will be specifically asked for at the times 
indicated in the Flow Chart above.
8.
Administration of BI 706321 in treatment R and T will be separated by at least 14 days.
9.
Blood collection takes place at the indicated times. Itraconazole will be administered immediately thereafter.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 5 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
FLOW CHART (cont’d)
Period
Visit
Day
Planned time (relative to 
drug administration) 
[h:min]
Approximate clock time  
of actual day [h:min]
Event and comment
Safety laboratory5
PK blood, BI 706321
12-lead ECG
Vital signs (body 
temperature BP, PR)
Questioning for AEs and 
concomitant therapy 7
Period 2/ Treatment T (BI 706321 + itraconazole) 8
3
-3
-73:00
08:00
Ambulatory visit, itraconazole administration
xB,2,3
x2
-2
-49:00
08:00
Ambulatory visit, itraconazole administration
x2
-1
-25:00
08:00
Ambulatory visit, itraconazole administration
xC,2
x2
1
-3:00
06:00
Admission to trial site2
x2
x2
x2
-1:00
08:00
Itraconazole administration
x2
0:00
09:00
BI 706321 administration
0:30
09:30
x
1:00
10:00
x
2:00
11:00
240 mL fluid intake
x
3:00
12:00
x
4:00
13:00
240 mL fluid intake, thereafter lunch4
x
x
x
x
5:00
14:00
x
6:00
15:00
x
7:00
16:00
Snack (voluntary)4
x
8:00
17:00
x
10:00
19:00
Dinner4
x
12:00
21:00
x
x 
2
23:00
08:00
Itraconazole administration
x2
24:00
09:00
Breakfast4
x
28:00
13:00
Lunch4
x
31:00
16:00
Snack (voluntary)4
34:00
19:00
Dinner4
x
x
3
46:00
07:00
Itraconazole administration,
discharge from trial site
xB,2
x9
x2
x2
x2
4
70:00
07:00
Ambulatory visit, itraconazole administration
x9
x2
5
94:00
07:00
Ambulatory visit, itraconazole administration
xC,2
x9
x2
6
118:00
07:00
Ambulatory visit, itraconazole administration
x9
x2
7
142:00
07:00
Ambulatory visit, itraconazole administration
xB,2
x9
x2
8
166:00
07:00
Ambulatory visit, itraconazole administration
x9
x2
9
190:00
07:00
Ambulatory visit, itraconazole administration
x9
x2
10
214:00
07:00
Ambulatory visit, itraconazole administration
xC,2
x9
x2
11
238:00
07:00
Ambulatory visit, itraconazole administration
x2
12
262:00
07:00
Ambulatory visit
x
x
14
310:00
07:00
Ambulatory visit
xC
x
x
16
358:00
07:00
Ambulatory visit
x
x
18
406:00
07:00
Ambulatory visit
x
x
20
454:00
07:00
Ambulatory visit
x
x
22
502:00
07:00
Ambulatory visit
x
x
24
550:00
07:00
Ambulatory visit
x
x
FU
4
25 to 35
End of trial (EoTrial) examination6
xD
x
x
x
1.
Subject must be informed and written informed consent obtained prior to starting any screening procedures. Screening 
procedures include physical examination, check of vital signs, ECG, safety laboratory (including drug screening), 
demographics (including determination of body height and weight, smoking status and alcohol history), relevant 
medical history, concomitant therapy and review of inclusion/exclusion criteria. 
2.
The time is approximate; the procedure is to be performed and completed within the 3 h prior to drug administration.
3.
Urine drug screening and alcohol breath test
4.
If several actions are indicated at the same time, the intake of meals will be the last action.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 6 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
5.
Letters A, B, C, and D define different sets of safety laboratory examinations (for details refer to Table 5.2.3: 1)
6.
At the end of trial visit the EoTrial examination includes physical examination, vital signs, ECG, safety laboratory, 
recording of AEs and concomitant therapies. 
7.
AEs and concomitant therapies will be recorded throughout the trial, but will be specifically asked for at the times 
indicated in the Flow Chart above.
8.
Administration of BI 706321 in treatment R and T will be separated by at least 14 days.
9.
Blood collection takes place at the indicated times. Itraconazole will be administered immediately thereafter.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 7 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
TABLE OF CONTENTS
TITLE PAGE ......................................................................................................1
CLINICAL TRIAL PROTOCOL SYNOPSIS ................................................2
FLOW CHART...................................................................................................4
TABLE OF CONTENTS ...................................................................................7
ABBREVIATIONS.......................................................................................... 11
1.
INTRODUCTION.................................................................................... 14
1.1
MEDICAL BACKGROUND............................................................................14
1.2
DRUG PROFILE...............................................................................................14
1.2.1
BI 706321 ...............................................................................................14
1.2.2
Itraconazole ...........................................................................................15
1.2.3
Residual Effect Period..........................................................................16
1.3
RATIONALE FOR PERFORMING THE TRIAL........................................16
1.4
BENEFIT - RISK ASSESSMENT ...................................................................16
1.4.1
Procedure-related risks ........................................................................16
1.4.2
Drug-related risks and safety measures..............................................17
1.4.2.1
Drug induced liver injury.........................................................17
1.4.2.2
BI 706321.................................................................................17
Drug-related events observed in clinical trials with BI 
706321 .......................................................................17
Risk assessment in the context of SARS-CoV-2 
infection.....................................................................17
Events predicted based on pharmacological properties 
/ preclinical information ............................................18
1.4.2.3
Itraconazole..............................................................................19
1.4.2.4
Potential drug-drug interaction between BI 706321 and 
itraconazole..............................................................................19
2.
TRIAL OBJECTIVES AND ENDPOINTS........................................... 21
2.1
MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS ......21
2.1.1
Main objectives......................................................................................21
2.1.2
Primary endpoints ................................................................................21
2.1.3
Secondary endpoint ..............................................................................21
2.2.2.2
Safety and tolerability..............................................................22
3.
DESCRIPTION OF DESIGN AND TRIAL POPULATION.............. 23
3.1
OVERALL TRIAL DESIGN AND PLAN ......................................................23

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 8 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
3.2
DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUPS........................................................................................23
3.3
SELECTION OF TRIAL POPULATION ......................................................24
3.3.1
Main diagnosis for trial entry..............................................................24
3.3.2
Inclusion criteria...................................................................................24
3.3.3
Exclusion criteria ..................................................................................24
3.3.4
Withdrawal of subjects from treatment or assessments ...................26
3.3.4.1
Discontinuation of trial treatment ............................................26
3.3.4.2
Withdrawal of consent to trial participation ............................27
3.3.4.3
Discontinuation of the trial by the sponsor..............................27
3.3.5
Replacement of subjects .......................................................................27
4.
TREATMENTS........................................................................................ 28
4.1
INVESTIGATIONAL TREATMENTS ..........................................................28
4.1.1
Identity of the Investigational Medicinal Products ...........................28
4.1.2
Selection of doses in the trial................................................................28
4.1.3
Method of assigning subjects to treatment groups ............................29
4.1.4
Drug assignment and administration of doses for each subject .......29
4.1.5
Blinding and procedures for unblinding ............................................30
4.1.6
Packaging, labelling, and re-supply ....................................................30
4.1.7
Storage conditions.................................................................................30
4.1.8
Drug accountability ..............................................................................30
4.2
OTHER TREATMENTS, EMERGENCY PROCEDURES, 
RESTRICTIONS ...............................................................................................31
4.2.1
Other treatments and emergency procedures....................................31
4.2.2
Restrictions............................................................................................31
4.2.2.1
Restrictions regarding concomitant treatment .........................31
4.2.2.2
Restrictions on diet and life style.............................................32
4.3
TREATMENT COMPLIANCE.......................................................................32
5.
ASSESSMENTS....................................................................................... 33
5.1
ASSESSMENT OF EFFICACY.......................................................................33
5.2
ASSESSMENT OF SAFETY............................................................................33
5.2.1
Physical examination ............................................................................33
5.2.2
Vital signs...............................................................................................33
5.2.3
Safety laboratory parameters..............................................................33
5.2.4
Electrocardiogram................................................................................36
5.2.5
Other safety parameters.......................................................................36
5.2.6
Assessment of adverse events...............................................................36
5.2.6.1
Definitions of adverse events...................................................36

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 9 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Adverse event ............................................................36
Serious adverse event ................................................37
AEs considered ‘Always Serious’.............................37
Adverse events of special interest .............................38
Intensity (severity) of AEs.........................................38
Causal relationship of AEs ........................................38
5.2.6.2
Adverse event collection and reporting ...................................39
AE collection.............................................................39
AE reporting to the sponsor and timelines ................40
Information required..................................................40
5.3
DRUG CONCENTRATION MEASUREMENTS AND 
PHARMACOKINETICS..................................................................................40
5.3.1
Assessment of pharmacokinetics .........................................................40
5.3.2
Methods of sample collection...............................................................40
5.3.2.1
Blood sampling for pharmacokinetic analysis of BI 706321...40
5.4
BIOBANKING ...................................................................................................42
5.5
OTHER ASSESSMENTS .................................................................................42
5.6
APPROPRIATENESS OF MEASUREMENTS.............................................42
6.
INVESTIGATIONAL PLAN.................................................................. 43
6.1
VISIT SCHEDULE............................................................................................43
6.2
DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS ................43
6.2.1
Screening period....................................................................................43
6.2.2
Treatment periods.................................................................................43
6.2.3
Follow-up period and trial completion ...............................................44
7.
STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE......................................................................................... 45
7.1
STATISTICAL DESIGN – MODEL ...............................................................45
7.2
NULL AND ALTERNATIVE HYPOTHESES ..............................................45
7.3
PLANNED ANALYSES....................................................................................45
7.3.1
Primary endpoint analyses...................................................................46
7.3.2
Secondary endpoint analyses ...............................................................47
7.3.4
Safety analyses.......................................................................................47
7.4
INTERIM ANALYSES .....................................................................................48
7.5
HANDLING OF MISSING DATA ..................................................................48
7.5.1
Safety......................................................................................................48
7.5.2
Pharmacokinetics..................................................................................49

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 10 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
7.6
RANDOMISATION ..........................................................................................49
7.7
DETERMINATION OF SAMPLE SIZE ........................................................49
8.
INFORMED CONSENT, TRIAL RECORDS, DATA 
PROTECTION, PUBLICATION POLICY, AND 
ADMINISTRATIVE STRUCTURE...................................................... 51
8.1
TRIAL APPROVAL, SUBJECT INFORMATION, INFORMED 
CONSENT ..........................................................................................................51
8.2
DATA QUALITY ASSURANCE .....................................................................52
8.3
RECORDS..........................................................................................................52
8.3.1
Source documents .................................................................................52
8.3.2
Direct access to source data and documents.......................................53
8.3.3
Storage period of records.....................................................................53
8.4
EXPEDITED REPORTING OF ADVERSE EVENTS .................................53
8.5
STATEMENT OF CONFIDENTIALITY AND SUBJECT PRIVACY.......54
8.5.1
Collection, storage and future use of biological samples and 
corresponding data ...............................................................................54
8.6
TRIAL MILESTONES .....................................................................................54
8.7
ADMINISTRATIVE STRUCTURE OF THE TRIAL ..................................55
9.
REFERENCES......................................................................................... 56
9.1
PUBLISHED REFERENCES...........................................................................56
9.2
UNPUBLISHED REFERENCES.....................................................................57
10. APPENDICES .......................................................................................... 59
11. DESCRIPTION OF GLOBAL AMENDMENT(S).............................. 60
11.1
GLOBAL AMENDMENT 1 .............................................................................60

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 11 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
ABBREVIATIONS
AE
Adverse event
AESI
Adverse events of special interest
ANOVA
Analysis of variance
AUC0-∞
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 extrapolated to infinity
AUC0-tz
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 to the last quantifiable data point
BA
Bioavailability
BI
Boehringer Ingelheim
BMI
Body mass index (weight divided by height squared)
BP
Blood pressure
bpm
Beats per minute
CA
Competent authority
CI
Confidence interval
Cmax
Maximum measured concentration of the analyte in plasma
CML
Clinical Monitor Local
COVID-19
SARS-CoV-2 induced disease
CRF
Case Report Form, paper or electronic (sometimes referred to as ‘eCRF’)
CTP
Clinical trial protocol
CTR
Clinical trial report
CV
Arithmetic coefficient of variation
CYP
Cytochrome P450
DDI
Drug-drug interaction
DILI
Drug induced liver injury
ECG
Electrocardiogram
eCRF
Electronic case report form
eDC
Electronic data capture
EDTA
Ethylenediaminetetraacetic acid
EoTrial
End of trial
EudraCT
European Clinical Trials Database

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 12 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
FIH
First in Human
FU
Follow-up
GCP
Good Clinical Practice
gCV
Geometric coefficient of variation
IB
Investigator’s brochure
ICF
Informed Consent Form
IEC
Independent Ethics Committee
IPD
Important protocol deviation
IRB
Institutional Review Board
ISF
Investigator site file
LC-MS/MS
Liquid chromatography with tandem mass spectrometry
LLOQ
Lower Limit of Quantitation
MDA
Methylenedioxyamphetamine
MDMA
Methylenedioxymethamphetamine
MedDRA
Medical Dictionary for Regulatory Activities
NOAEL
No Observed Adverse Effect Level
NOD
Nucleotide Oligomerization Domain
PCR
Polymerase Chain Reaction
P-gp
P-glycoprotein
PK
Pharmacokinetic(s)
PKS
Pharmacokinetic set
PMDA
Pharmaceuticals and Medicinal Devices Agency
PR
Pulse rate
q.d.
Quaque die, once daily
QT
Time between start of the Q-wave and the end of the T-wave in an 
electrocardiogram
QTc
QT interval corrected for heart rate using the method of Fridericia (QTcF) 
or Bazett (QTcB)
R
Reference treatment
REP
Residual effect period
SAE
Serious adverse event
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
SCR
Screening
SmPC
Summary of Product Characteristics
SOP
Standard operating procedure

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 13 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
SRD
Single-rising dose
T
Test product or treatment
TS
Treated set
tz
Time of last measurable concentration of the analyte in plasma
TSAP
Trial statistical analysis plan
ULN
Upper limit of normal
XTC
Ecstasy 

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 14 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1.
INTRODUCTION
1.1
MEDICAL BACKGROUND
For more details on medical background refer to the Investigator’s Brochure (IB) 
[c26475781].
1.2
DRUG PROFILE
1.2.1
BI 706321
For details on the nonclinical pharmacology, pharmacokinetics in animals and toxicology 
results refer to the IB [c26475781].
As of 28 May 2020, preliminary results are available from Part I of the first-in-human Trial 
1425-0001. A total of 46 healthy male subjects received single oral ascending doses of 
 BI 706321 and 15 subjects received placebo. 
All tested doses of BI 706321 have been well tolerated. The observed AEs did not follow any 
specific pattern of distribution and no dose dependency was observed. Neither SAE nor 
severe AE were observed. The frequency of subjects with at least one treatment-emergent AE 
ranged from 0 to 60% on BI 706321 dose groups as compared to 40% on placebo. AEs 
reported in >1 subject on active treatment were coded as diarrhea (n=2, loose stool 
 
and watery stool 
) and nasopharyngitis (n=
. A total of 5 drug related 
AEs have been observed on active treatment: dry lips 
, loose stool 
 dizziness 

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 15 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
 watery stool 
 and generalized sensation of cold 
 All these AEs were 
of mild intensity. 
The “generalized sensation of cold” was accompanied by a slightly increased body 
temperature (37.4°C) and an increased CRP-value (35.4 mg/l). Beyond this no specific 
changes of laboratory parameters have been observed in the tested dose groups. Clinical 
monitoring did not show any relevant changes of ECG-parameters and vital signs
[c26475781].
As of 21 September 2020, an additional 16 subjects were dosed with 
 BI 706321 as 
part of the blinded first and second dose cohorts of the multiple rising dose Trial 1425-0002.  
Both tested doses of BI 706321 were well-tolerated and neither SAE nor severe AE were 
observed.  
1.2.2
Itraconazole
Absorption of itraconazole solution is fast with maximum plasma concentration being 
reached within 2.5 h after oral administration in fasting condition. Bioavailability of 
itraconazole liquid increases by 30% when given under fasting condition compared to 
administration together with food [R20-2709]. Mean peak plasma concentrations were 547.7 
ng/mL after a single dose of 200 mg itraconazole solution (fasting) and 1965 ng/mL after 15 
days of daily treatment with 200 mg itraconazole solution (fasting). Pharmacokinetics of 
itraconazole is non-linear. The half-life of itraconazole after multiple doses of 200 mg once 
daily with solution formulation was about 40 h [R17-3742].
In the liver, itraconazole is metabolised extensively to more than 30 metabolites [R17-3743]. 
Its main metabolite, hydroxy-itraconazole, accounts for about twice the concentration of 
plasma itraconazole at trough. It has been shown in vitro that CYP3A4 is mainly responsible 
for the formation of this metabolite [R20-2709]. FDA classifies itraconazole as strong index 
inhibitor of CYP3A and as inhibitor of P-glycoprotein (P-gp) [R18-0241]. However, not only 
itraconazole contributes to the in vivo inhibition of CYP3A observed after itraconazole
administration but also three of its metabolites (hydroxy-itraconazole, keto-itraconazole, and 
N desalkyl-itraconazole) [R10-1102].
For a more detailed description of itraconazole, please refer to the German Summary of 
Product Characteristics (SmPC) for Sempera® Liquid 10 mg/ml [R20-2709].

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 16 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1.2.3
Residual Effect Period
The Residual Effect Period (REP, i.e., the period after the last dose with measurable drug 
levels and/or pharmacodynamic effects still likely to be present) of BI 706321 is assumed to 
be 8 days, i.e. based on 
terminal t1/2 seen in the FIH trial 1425-0001.
When given together with itraconazole (Treatment T), it is expected that plasma exposure of 
BI 706321 could be increased (albeit within the exposures explored in the clinical trial 1425-
0001), and the time of relevant plasma exposure could be prolonged. This might result in a 
prolonged period in which adverse effects could potentially occur. 
For the use of itraconazole in Treatment T, the REP is defined as 8 days after last 
administration of itraconazole on Day 11 in Period 2.
1.3
RATIONALE FOR PERFORMING THE TRIAL
Based on in vitro data, BI 706321 is mainly metabolized via CYP 3A4. Additionally, 
BI 706321 is an in vitro substrate of P-glycoprotein (P-gp).
Therefore, in this trial, the focus is on the drug-drug interaction (DDI) victim potential of 
BI 706321 with regard to CYP3A4 and P-gp as this may lead to clinically relevant increases 
in exposures with potential impact on patient safety.
Itraconazole is chosen for this trial as perpetrator drug, as this drug is recommended as strong 
inhibitor of CYP3A by EMA and PMDA [P15-06991, P15-06298], and as strong index 
inhibitor of CYP3A and P-gp by FDA [R18-0241]. 
Moreover, safety and tolerability of itraconazole were acceptable in previous DDI trials
[c02336088, c03355329, c08928447].
1.4
BENEFIT - RISK ASSESSMENT
Participation in this clinical trial is without any (therapeutic) benefit for healthy subjects. 
Their participation, however, is of major importance for the development of a drug which 
might improve the therapy of patients with Crohn’s disease.
Subjects are exposed to risks of study procedures and risks related to the exposure to the trial 
medication.
1.4.1
Procedure-related risks
The use of an indwelling venous catheter or venepuncture for e.g. blood sampling may result 
in mild bruising, and in rare cases, in transient inflammation of the wall of the vein, or nerve 
injury, potentially resulting in paraesthesia, reduced sensibility, and/or pain for an indefinite 
period, as well as in feeling of lightheadedness or in syncope.
The total volume of blood withdrawn per subject during the entire study will not exceed the 
volume of a normal blood donation (500 mL). No health-related risk to healthy subjects is 
expected from withdrawal of this volume of blood.
ECG electrodes may cause local and typically transient skin reactions.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 17 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1.4.2
Drug-related risks and safety measures
1.4.2.1
Drug induced liver injury
Although rare, a potential for drug-induced liver injury (DILI) is under constant surveillance 
by sponsors and regulators. Therefore, this trial requires timely detection, evaluation, and 
follow-up of laboratory alterations in selected liver laboratory parameters to ensure subjects´ 
safety; see also Section 5.2.6.1.4, adverse events of special interest.
1.4.2.2
BI 706321
Drug-related events observed in clinical trials with BI 706321
In Part I of the first-in-human trial 1425-0001, single ascending doses of BI 706321 have
been well tolerated up to the maximum tested dose of
 
[ref. Section 1.2.1].
Furthermore, multiple dose administration of 
 q.d. over 14 days have been well 
tolerated in the first and second dose cohorts of the ongoing multiple rising dose trial 1425-
0002.
As with all drugs, the potential for hypersensitivity and allergic reactions has to be taken into 
consideration when BI 706321 is administered.
Risk assessment in the context of SARS-CoV-2 infection
Participation in this clinical trial will increase the risk of COVID-19 exposure due to 
traveling to the study site and completing the protocol-defined procedures at the study site. A 
risk management plan has been set up at the clinical site that detail specific precautionary 
measures, (e.g. hygiene rules, wearing of face masks, physical distancing), screening for 
SARS-CoV-2, and trial drug discontinuation in subjects with COVID-19 infection.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 18 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Events predicted based on pharmacological properties / preclinical information

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 19 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1.4.2.3
Itraconazole
In this trial, itraconazole will be used in a standard clinical dose of 200 mg once daily for 14 
days. Multiple dosing of 200 mg itraconazole up to 15 days was of acceptable tolerability in 
healthy subjects [c02336088, c03355329, c08928447, R17-3742]. 
For a detailed description of the potential risks of itraconazole treatment in patients, please 
refer to the German Summary of Product Characteristics (SmPC) for Sempera® Liquid 
10 mg/ml [R20-2709].
In order to address the risk of hepatotoxicity, only subjects with normal liver enzyme values 
will be included into the study. Safety laboratory parameters will be monitored closely. An 
individual subject will be removed from trial treatment if the subject shows an elevation of 
AST and/or ALT ≥3-fold ULN combined with an elevation of total bilirubin ≥2-fold ULN 
(measured in the same blood sample, see Section 3.3.4.1). 
Further, most of the reported cases of serious hepatotoxicity during itraconazole treatment 
occurred in patients that suffered from concomitant liver diseases, had other significant 
diseases, or took concomitant hepatotoxic drugs. Subjects with liver diseases or a medical 
history of drug-induced liver failure are excluded from trial participation. 
Itraconazole has shown a dose-related increase in maternal toxicity, embryotoxicity and 
teratogenicity in nonclinical studies at high doses, and therefore itraconazole must not be 
used during pregnancy. Woman of childbearing potential have to use a highly effective 
method of contraception until the menstrual period after the last itraconazole dose [R20-2709, 
R18-2643]. For risk mitigation, only male subjects will be included into this clinical trial.
Considering these safety measures and taking into account the reported acceptable tolerability 
of itraconazole, the planned administration of itraconazole does not represent an undue risk to 
healthy male volunteers.
1.4.2.4
Potential drug-drug interaction between BI 706321 and itraconazole
It is likely that concomitant administration of BI 706321 with itraconazole leads to an 
increase of plasma concentrations and terminal half-live of BI 706321. The effect of 
itraconazole in increasing Cmax and AUC of other drugs can be as high as 3.4-fold and 11-
fold, respectively, as seen with oral midazolam, a sensitive CYP3A4 substrate, when co-
administered with oral itraconazole 200 mg/d [R01-0516, R20-2709]. 

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 20 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Inhibition of P-gp may increase exposure of sensitive P-gp substrates like fexofenadine by 
factor 3-4 [R08-1652, P07-13746] and increase digoxin exposure by ~1.7-fold [R15-3252]. 
Therefore, a low dose of 
 BI 706321 has been selected for this trial (see Section 4.1.2) to 
ensure that BI 706321 plasma concentrations, even in case of a substantial increase when 
given with itraconazole, are within the range of concentrations that were explored in the SRD 
part of trial 1425-0001
and that were associated with good safety and 
tolerability (ref. Section 1.2.1).

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 21 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
2.
TRIAL OBJECTIVES AND ENDPOINTS
2.1
MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS
2.1.1
Main objectives
The main objective of this trial is to investigate the effect on the exposure of BI 706321 in 
plasma when given as oral single dose together with multiple oral doses of itraconazole (Test, 
T) as compared to when given alone as oral single dose (Reference, R).
2.1.2
Primary endpoints
The following pharmacokinetic parameters will be determined for BI 706321:

AUC0-∞(area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 extrapolated to infinity)

Cmax (maximum measured concentration of the analyte in plasma)
2.1.3
Secondary endpoint
The following pharmacokinetic parameter will be determined for BI 706321:

AUC0-tz (area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 to the last quantifiable data point)

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 22 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
2.2.2.2
Safety and tolerability
Safety and tolerability of the treatments will be assessed based on:  

Adverse events (including clinically relevant findings from the physical examination)

Safety laboratory tests

12-lead ECG

Vital signs (body temperature, blood pressure, pulse rate)

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 23 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
3.
DESCRIPTION OF DESIGN AND TRIAL POPULATION
3.1
OVERALL TRIAL DESIGN AND PLAN
The study will be performed as an open-label, two-treatment, two-period, fixed sequence 
design trial in healthy male subjects in order to compare the test treatment (T) to the reference 
treatment (R). The treatments will be one oral single dose of 
 BI 706321 administered as 
tablet formulation together with multiple oral doses of 200 mg itraconazole as oral solution 
formulation (concentration: 10 mg/mL) (treatment T) and one single dose of 
 BI 706321 
as tablet given alone (R).
In both treatments, BI 706321 is administered to subjects in the fasting state. In the first 
treatment period (Period 1, Visit 2), all subjects are planned to undergo treatment R, and in 
the second treatment period (Period 2, Visit 3), all subjects are planned to undergo treatment 
T. For details, refer to Section 4.1.
There will be a washout period of at least 14 days between the administrations of BI 706321.
Figure 3.1: 1
Trial design
An overview of all relevant trial activities is provided in the Flow Chart. For visit schedule 
and details of trial procedures at selected visits, refer to Sections 6.1 and 6.2, respectively.
3.2
DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUPS
For drug interaction trials, the crossover design is preferred because of its efficiency: since 
each subject serves as his/her own control, the comparison between treatments is based on an 
intra-subject comparison, thus removing inter-subject variability from the comparison 
between treatments [R94-1529]. 
Because of the long half-life (about 40 h) of itraconazole and its metabolites, a two-period 
fixed sequence design was selected, with administration of itraconazole in the second study 
period only. This design is not expected to lead to systematic errors in the estimation of the 
treatment effects since nonspecific time-effects are unlikely due to the short trial duration. 
For itraconazole studies, this design is recommended by the Innovation and Quality in 
Screening
Period 1
Period 2
End-of-trial
BI 706321
Itraconazole
≥3 day

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 24 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Pharmaceutical Development’s 
 [R17-
3744]. 
For this PK drug-drug interaction trial, open-label treatment is acceptable, because the 
primary and secondary endpoints of this trial are PK endpoints derived from measurement of 
plasma concentrations of BI 706321. These endpoints are not expected to be affected by 
knowledge of treatment.
3.3
SELECTION OF TRIAL POPULATION
It is planned that 14 healthy male subjects will enter the study. They will be recruited from 
the volunteers' pool of the trial site.
Due to the reproduction toxicity itraconazole has shown in nonclinical studies, only male 
subjects will be included in this trial.
A log of all subjects enrolled into the trial (i.e. who have signed informed consent) will be 
maintained in the ISF irrespective of whether they have been treated with investigational drug 
or not.
3.3.1
Main diagnosis for trial entry
The study will be performed in healthy subjects.
3.3.2
Inclusion criteria
Subjects will only be included in the trial if they meet the following criteria:
1. Healthy male subjects according to the assessment of the investigator, as based on a 
complete medical history including a physical examination, vital signs (body temperature, 
BP, PR), 12-lead ECG, and clinical laboratory tests 
2. Age of 18 to 50 years (inclusive)
3. BMI of 18.5 to 29.9 kg/m2 (inclusive) 
4. Signed and dated written informed consent prior to admission to the study, in accordance 
with GCP and local legislation
3.3.3
Exclusion criteria
Subjects will not be allowed to participate, if any of the following general criteria apply:
1. Any finding in the medical examination (including BP, PR or ECG) deviating from 
normal and assessed as clinically relevant by the investigator
2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, 
diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the
range of 45 to 90 bpm
3. Any laboratory value outside the reference range that the investigator considers to be of 
clinical relevance
4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 25 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or 
hormonal disorders
6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the 
pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
7. Diseases of the central nervous system (including but not limited to any kind of seizures 
or stroke), and other relevant neurological or psychiatric disorders 
8. History of relevant orthostatic hypotension, fainting spells, or blackouts
9. Relevant chronic or acute infections
10. History of relevant allergy or hypersensitivity (including allergy to the trial medication or 
its excipients) 
11. Use of drugs within 30 days of planned administration of trial medication that might 
reasonably influence the results of the trial (including drugs that cause QT/QTc interval
prolongation)
12. Intake of an investigational drug in another clinical trial within 60 days of planned  
administration of investigational drug in the current trial, or concurrent participation in 
another clinical trial in which investigational drug is administered
13. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
14. Inability to refrain from smoking on specified trial days
15. Alcohol abuse (consumption of more than 24 g per day) and unwillingness/inability to 
refrain from intake of alcoholic beverages from 48 hours prior to first trial medication 
administration and until 7 days post last trial medication administration
16. Drug abuse or positive drug screening
17. Blood donation of more than 100 mL within 30 days of planned administration of trial 
medication or intended blood donation during the trial
18. Intention to perform excessive physical activities within one week prior to the 
administration of trial medication or during the trial
19. Inability to comply with the dietary regimen of the trial site
20. A marked prolongation of QT/QTc interval (such as QTc intervals that are repeatedly 
greater than 450 ms) or any other relevant ECG finding at screening
21. A history of additional risk factors for Torsade de Pointes (such as heart failure, 
hypokalaemia, or family history of Long QT Syndrome)
22. Subject is assessed as unsuitable for inclusion by the investigator, for instance, because 
the subject is not considered able to understand and comply with study requirements, or 
has a condition that would not allow safe participation in the study 
23. Liver enzymes (ALT, AST, GGT) above upper limit of normal at the screening 
examination, confirmed by a repeat test 
24. History of drug induced liver injury
25. History of heart failure, or any evidence of ventricular dysfunction 
26. Known sorbitol/polyols intolerance
27. During COVID-19 pandemic: laboratory test indicative of an ongoing SARS-CoV-2 
infection

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 26 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
For study restrictions, refer to Section 4.2.2.
3.3.4
Withdrawal of subjects from treatment or assessments
Subjects may discontinue trial treatment or withdraw consent to trial participation as a whole 
(‘withdrawal of consent’) with very different implications; please see sections 3.3.4.1 and 
3.3.4.2 below.
If a subject is removed from or withdraws from the trial prior to the first administration of 
trial medication, the data of this subject will not be entered in the case report form (CRF) and 
will not be reported in the clinical trial report (CTR). If a subject is removed from or 
withdraws from the trial after the first administration of trial medication, this will be 
documented and the reason for discontinuation must be recorded in the CRF; in addition, the 
data will be included in the CRF and will be reported in the CTR. At the time of 
discontinuation, a complete end of trial examination will be performed, if possible, and the 
information will be recorded in the CRF. If the discontinuation occurs before the end of the 
REP (see Section 1.2.3), the discontinued subject should if possible be questioned for AEs 
and concomitant therapies at or after the end of the REP in order to ensure collection of AEs 
and concomitant therapies throughout the REP, if not contrary to any consent withdrawal of 
the subject.
3.3.4.1
Discontinuation of trial treatment
An individual subject will discontinue trial treatment if:
1. The subject wants to discontinue trial treatment, without the need to justify the decision
2. The subject has repeatedly shown to be non-compliant with important trial procedures 
and, in the opinion of both, the investigator and sponsor representative, is not willing or 
able to adhere to the trial requirements in the future.
3. The subject needs to take concomitant medication that interferes with the investigational 
medicinal product or other trial treatment
4. The subject can no longer receive trial treatment for medical reasons (such as surgery, 
adverse events [AEs], or diseases)
5. An AE or clinically significant laboratory change or abnormality occurs that the 
investigator assesses as warranting discontinuation of treatment. This may include:

The subject has an elevation of AST and/or ALT ≥3-fold ULN

The subject has a serious adverse reaction or a severe non-serious adverse reaction
6. The subject has an elevation of AST and/or ALT ≥3-fold ULN and an elevation of total 
bilirubin ≥2-fold ULN (measured in the same blood sample) and/or needs to be followed 
up according to the DILI checklist provided in the ISF
In addition to these criteria, the investigator may discontinue subjects at any time based on 
his or her clinical judgment.
Even if the trial treatment is discontinued, the subject remains in the trial and, given his/her 
agreement, will undergo the procedures for early treatment discontinuation and follow up as 
outlined in the Flow Chart and section 6.2.3.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 27 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
3.3.4.2
Withdrawal of consent to trial participation
Subjects may withdraw their consent to trial participation at any time without the need to 
justify the decision. If a subject wants to withdraw consent, the investigator should be 
involved in the discussion with the subject and explain the difference between trial treatment 
discontinuation and withdrawal of consent to trial participation, as well as explain the options 
for continued follow up after trial treatment discontinuation, please see section 3.3.4.1 above
3.3.4.3
Discontinuation of the trial by the sponsor
Boehringer Ingelheim reserves the right to discontinue the trial at any time for any of the 
following reasons:
1. Failure to meet expected enrolment goals overall or at a particular trial site
2. New toxicological findings, serious adverse events, or any safety information invalidating
the earlier positive benefit-risk-assessment. More specifically, the trial will be terminated 
if more than 50% of the subjects have drug-related and clinically relevant adverse events 
of moderate or severe intensity, or if at least 1 drug-related serious adverse event is 
reported
3. Violation of GCP, or the CTP, or the contract with BI impairing the appropriate conduct 
of the trial
4. The sponsor decides to discontinue the further development of the investigational product
The investigator / trial site will be reimbursed for reasonable expenses incurred in case of 
trial termination (except if item 3 applies).
3.3.5
Replacement of subjects
Subjects withdrawn due to drug related adverse events will not be replaced. In case more than 
2 subjects do not complete the trial, the Clinical Trial Leader together with the Trial 
Pharmacokineticist and the Trial Statistician are to decide, if and how many subjects will be 
replaced. A replacement subject will be assigned a unique trial subject number.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 28 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
4.
TREATMENTS
4.1
INVESTIGATIONAL TREATMENTS
The investigational product BI 706321 as tablet formulation will be supplied by BI Pharma 
GmbH & Co. KG.
Itraconazole oral solution will be obtained from a public pharmacy. 
4.1.1
Identity of the Investigational Medicinal Products
The characteristics of the trial products are given below:
Trial product 1
Substance:
BI 706321
Pharmaceutical formulation: Tablet, film-coated
Source:
BI Pharma GmbH & Co. KG, Germany
Unit strength:
Posology:
1-0-0
Route of administration:
Oral
Duration of use:
Single dose in treatments R and T
Trial product 2
Name:
Sempera® Liquid 10 mg/mL 
Substance:
Itraconazole
Pharmaceutical formulation: Oral solution
Source:
Public pharmacy
Holder of marketing
authorisation:
Unit strength:
10 mg/mL
Posology:
20 mL-0-0
Route of administration:
Oral
Duration of use:
14 days in treatment T
4.1.2
Selection of doses in the trial
Perpetrator (itraconazole)
The dose of itraconazole selected for this trial reflects standard clinical doses, is considered 
sufficient to yield significant CYP3A and P-gp inhibition and has been used successfully and 
safely in previous drug-drug-interaction trials (c02336088, c03355329, c08928447).

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 29 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Victim (BI 706321)
Based on in vitro data, CYP3A is the major CYP isoform responsible for the metabolism of 
BI 706321. Additionally, BI 706321 is an in vitro substrate of P-gp. Thus, concomitant 
administration of BI 706321 with the strong CYP3A inhibitor itraconazole may result in 
substantial increases of BI 706321 plasma concentrations.
For the current trial, a dose of 
 BI 706321 is selected, in order to ensure that BI 706321 
plasma concentrations, even in case of a substantial increase when given with itraconazole, 
are within the range of concentrations that were explored in the SRD part of trial 1425-0001 
and that were associated with good safety and tolerability (ref. Section 1.2.1).
4.1.3
Method of assigning subjects to treatment groups
There is only one treatment sequence investigated in this trial, and each subject will be 
allocated to the same treatment sequence (R-T). The subjects will be allocated to a study 
subject number by the method “first come-first served” prior to first administration of trial 
medication in the morning of Day 1 of Visit 2. Once a subject number has been assigned, it 
cannot be reassigned to any other subject.
All subjects may be treated in one cohort, i.e. all subjects may receive treatment on the same 
calendar day. In case this is not feasible (e.g., due to logistical or recruitment reasons), the 
group may be split into several cohorts as required. 
Treatment of all subjects on the same calendar day is acceptable (for safety margin to 
exposure reached in previous SRD trial 1425-0001 refer to Section 1.4.2.1.1; for discussion 
of study-associated risks and safety measures see Section 1.4).
4.1.4
Drug assignment and administration of doses for each subject
The treatments to be evaluated are outlined in Table 4.1.4: 1 below. All subjects will receive 
the 2 treatments in a fixed order.
Table 4.1.4: 1
Dosage and treatment schedule
Treatment 
period
Treatment
Substance
Formulation
Unit 
strength
Dosage
Total  
dose
1
R (Reference)
BI 706321
Tablet, 
film-coated
1 tablet as single dose
(Day 1)
2
T (Test)
BI 706321
Itraconazole
Tablet, 
film-coated
Oral solution
10 mg/mL
1 tablet as single dose
(Day 1)
20 mL (200 mg) qd for 14 days 
(Days -3 to 11)
2800 mg
Administration of trial medication will be performed after subjects have fasted overnight;
fasting is to start no later than 10 h before the scheduled dosing of BI 706321 or 9 hours 
before itraconazole administration. The investigator (or authorised designee) will administer 
the trial medication as an oral dose together with about 240 mL of water to subjects who are 
in a standing or sitting position. For drug administration, the so-called four-eye principle 
(two-person rule) should be applied. For this, one authorised employee of the trial site should 

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 30 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
witness the administration of trial medication, and – if applicable – its preparation (e.g. 
reconstitution), if correct dosage cannot be ensured otherwise.
Subjects will be kept under close medical surveillance until at least 24 hours and 46 hours 
after administration of BI 706321 in Visit 2 and Visit 3, respectively. During the first 4 h 
after administration of BI 706321, subjects are not allowed to lie down (i.e. no declination of 
the upper body of more than 45 degrees from upright posture).
The treatments with BI 706321 will be separated by a wash-out phase of at least 14 days.
4.1.5
Blinding and procedures for unblinding
This Phase I trial will be handled in an open fashion throughout (that is, during the conduct,
including data cleaning and preparation of the analysis). This is considered acceptable 
because the potential for bias seems to be low and does not outweigh practical considerations.
Due to the open design of this trial, emergency envelopes will not be provided.
4.1.6
Packaging, labelling, and re-supply
BI 706321
BI 706321 tablets will be provided by BI. They will be packaged and labelled in accordance 
with local law and the principles of Good Manufacturing Practice. 
For details of packing and the description of the label, refer to the ISF.
The telephone number of the sponsor and the name, address and telephone number of the trial 
site are provided in the subject information form. The EudraCT number is indicated on the 
title page of this protocol as well as on the subject information and informed consent forms.
No re-supply is planned.
Itraconazole
Itraconazole oral solution will be obtained by the clinical trial site from a public pharmacy. 
The drug will be dispensed out of the original, unmodified packages.
4.1.7
Storage conditions
Drug supplies will be kept in their original packaging and in a secure limited access storage 
area in accordance with the recommended (labelled) storage conditions. If necessary, a 
temperature log must be maintained to make certain that the drug supplies are stored at the 
correct temperature. If the storage conditions are found to be outside the specified range, the 
local clinical monitor (as provided in the list of contacts) is to be contacted immediately.
4.1.8
Drug accountability
The investigator or designee will receive the investigational drugs delivered from the sponsor
following requirements are fulfilled:

Approval of the clinical trial protocol by the IRB / ethics committee

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 31 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018

Availability of a signed and dated clinical trial contract between the sponsor and the 
investigational site

Approval/notification of the regulatory authority,  e.g. competent authority

Availability of the curriculum vitae of the Principal Investigator

Availability of a signed and dated clinical trial protocol  
Only authorised personnel documented in the form 'Trial Staff List' may dispense medication 
to trial subjects. The trial medication must be administered in the manner specified in the 
CTP.
The investigator or designee must maintain records of the product’s delivery to the trial site, 
the inventory at the site, the use by each subject, and the disposal of unused products.These 
records will include dates, quantities, batch / serial numbers, expiry ('use-by') dates, and the 
unique code numbers assigned to the investigational medicinal product and trial subjects. The 
investigator or designee will maintain records that document adequately that the subjects 
were provided the doses specified by the CTP and reconcile all investigational medicinal 
products received from the sponsor. At the time of disposal of remaining trial medication, the 
investigator or designee must verify that no remaining supplies are in the investigator’s 
possession.
All unused medication will be disposed of locally by the trial site upon written authorisation 
of the trial clinical monitor. Receipt, usage and disposal of trial medication must be 
documented on the appropriate forms. Account must be given for any discrepancies.
4.2
OTHER TREATMENTS, EMERGENCY PROCEDURES, 
RESTRICTIONS
4.2.1
Other treatments and emergency procedures
There are no special emergency procedures to be followed. No additional treatment is 
planned. However, if adverse events require treatment, the investigator can authorise 
symptomatic therapy. In those cases, subjects will be treated as necessary and, if required, 
kept under supervision at the trial site or transferred to a hospital until all results of medical 
evaluations are acceptable.
4.2.2
Restrictions
4.2.2.1
Restrictions regarding concomitant treatment
In principle, no concomitant therapy is allowed. All concomitant or rescue therapies will be 
recorded (including time of intake on study days) on the appropriate pages of the CRF.
Known inhibitors/inducers of CYP3A4 or P-gp activity, drugs with a known hepatotoxicity 
profile, drugs which are contraindicated to be co-administered with itraconazole [R20-2709]
should be avoided during the entire study; if necessary, short term use of ibuprofen is 
acceptable.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 32 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
4.2.2.2
Restrictions on diet and life style
Poppy-seeds containing foods should not be consumed starting 3 days before the first drug 
administration in each treatment period, in order to avoid false-positive results in the drug-
screen.
While admitted to the trial site, the subjects will be instructed not to consume any foods or 
drinks other than those provided by the staff. Standardised meals will be served at the times
indicated in the Flow Chart. No food is allowed within 10 h before and for at least 4 h after 
intake of BI 706321. Subjects will be advised to not consume any food within 9 h before and 
1 h after itraconazole administrations.
On Day 1, from 1 h before intake of BI 706321 (Period 1) or itraconazole (Period 2), 
respectively, fluid intake is restricted to the water administered with the drug, and an 
additional 240 mL of water at 2 h and 4 h post-dose (mandatory for all subjects). From lunch 
until 23 h post-dose BI 706321, total fluid intake is restricted to 3000 mL.
Grapefruits, Seville oranges (sour or bitter oranges) and their juices, and dietary supplements 
and products containing St. John's wort (Hypericum perforatum) are not permitted from 7 
days before the first administration of trial medication in Period 1 until after the last PK 
sample of Period 2 is collected. 
Alcoholic beverages are not permitted from 3 days before the first administration of trial 
medication in Period 1 until after the last PK sample in Period 2 is collected.
Methylxanthine-containing drinks or foods (such as coffee, tea, cola, energy drinks, or 
chocolate) are not allowed from 10 h before until 24 h after administration of BI 706321.
Smoking is not allowed during in-house confinement. 
Excessive physical activity (such as competitive sport) should be avoided from 7 days before 
the first administration of trial medication until the end of trial examination.
Direct exposure to the sun or exposure to solarium radiation should be avoided during the 
entire study.
4.3
TREATMENT COMPLIANCE
Compliance will be assured by administration of all trial medication in the study centre under 
supervision of the investigating physician or a designee. The measured plasma concentrations 
of trial medication will provide additional confirmation of compliance.
Subjects who are non-compliant (for instance, who do not appear for scheduled visits or 
violate trial restrictions) may be removed from the trial and the CRF will be completed 
accordingly (for further procedures, please see Section 3.3.4).

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 33 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
5.
ASSESSMENTS
5.1
ASSESSMENT OF EFFICACY
Not applicable.
5.2
ASSESSMENT OF SAFETY
5.2.1
Physical examination
At screening, the medical examination will include demographics, height and body weight, 
smoking and alcohol history (result not mandatory to be entered into CRF or to be reported),
relevant medical history and concomitant therapy, review of inclusion and exclusion criteria, 
review of vital signs (body temperature, BP, PR), 12-lead ECG, laboratory tests, and a 
physical examination. At the end of trial examination, it will include review of vital signs, 12-
lead ECG, laboratory tests, and a physical examination.
5.2.2
Vital signs
Systolic and diastolic blood pressures (BP) as well as pulse rate (PR) will be measured by a 
blood pressure monitor (Dinamap, 
) at the times 
indicated in the Flow Chart, after subjects have rested for at least 5 min in a supine position. 
All recordings should be made using the same type of blood pressure recording instrument on 
the same arm, if possible. Body temperature will be measured using ear thermometer. 
5.2.3
Safety laboratory parameters
For the assessment of laboratory parameters, blood and urine samples will be collected by the 
trial site at the times indicated in the Flow Chart after the subjects have fasted for at least 
10 h. For retests, at the discretion of the investigator or designee, overnight fasting is not 
required.
The parameters that will be determined are listed in Tables 5.2.3: 1 and 5.2.3: 2. Reference 
ranges will be provided in the ISF. 
Manual differential white blood cell count or urine sediment examinations will only be 
performed if there is an abnormality in the automatic blood cell count or in the urinalysis, 
respectively.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 34 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Table 5.2.3: 1
Routine laboratory tests
Functional lab group
BI test name [comment/abbreviation]
A1
B1
C1
D1
Haematology
Haematocrit
Haemoglobin
Red Blood Cell Count/Erythrocytes 
Reticulocytes, absol.
Reticulocytes/Erythrocyte
White Blood Cells/Leukocytes
Platelet Count/Thrombocytes (quant)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
--
--
--
--
--
--
--
X
X
X
X
X
X
X
Automatic WBC 
differential, relative
Neutrophils/Leukocytes; Eosinophils/Leukocytes; Basophils/ 
Leukocytes; Monocytes/Leukocytes; Lymphocytes/Leukocytes 
X
X
--
X
Automatic WBC 
differential, absolute 
Neutrophil, absol.; Eosinophils, absol.; Basophils, absol.; 
Monocytes, absol.; Lymphocytes, absol.
X
X
--
X
Manual differential 
WBC (if automatic
differential WBC is 
abnormal)
Neut. Poly (segs)/Leukocytes; Neut. Poly (segs), absol.; Neutrophils 
Bands/Leukocytes; Neutrophils Bands, absol.;
Eosinophils/Leukocytes; Eosinophils, absol.; Basophils/Leukocytes; 
Basophils, absol.; Monocytes/Leukocytes; Monocytes, absol.; 
Lymphocytes/Leukocytes; Lymphocytes, absol.
Coagulation
Activated Partial Thromboplastin Time 
Prothrombin time
INR (International Normalization Ratio)
Fibrinogen
X
X
X
X
--
--
--
X
--
--
--
--
X
X
X
X
Enzymes
AST [Aspartate transaminase] /GOT, SGOT 
ALT [Alanine transaminase] /GPT, SGPT
Alkaline Phosphatase
Gamma-Glutamyl Transferase)
Creatine Kinase [CK]
Creatine Kinase Isoenzyme MB [only if CK is elevated]
Lactic Dehydrogenase 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
--
--
--
X
X
X
X
X
X
X
Hormones
Thyroid Stimulating Hormone 
X
--
--
--
Substrates
Glucose (Plasma)
Creatinine
GFR/ CKD-EPI3
Bilirubin, Total 
Bilirubin, Direct
Protein, Total
C-Reactive Protein (Quant)  
Haptoglobin
Ferritin
Cholesterol, total 
X
X
X
X
X
X
X
X
X
X
X
X
--
X
X
X
X
--
--
--
--
--
--
X
X
--
--
--
--
--
X
X
X
X
X
X
X
X
X
X
Electrolytes
Sodium
Potassium
X
X
X
X
--
--
X
X
Urinalysis2 (Stix)
Urine Nitrite (qual)
Urine Protein (qual)
Urine Glucose (qual)
Urine Ketone (qual)
Urobilinogen (qual)
Urine Bilirubin (qual)
Urine RBC/Erythrocytes (qual)
Urine WBC/Leucocytes (qual)
Urine pH
X
X
X
X
X
X
X
X
X
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
X
X
X
X
X
X
X
X
X
Urine sediment2
Only positive findings will be reported (for instance, the presence of 
sediment bacteria, casts in sediment, squamous epithelial cells, 
erythrocytes, leukocytes)

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 35 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1
A: parameters to be determined at Visit 1 (screening examination)
B: parameters to be determined at Visit 2 and 3 (for study days and time points refer to Flow Chart)
C: parameters to be determined at Visit 3 (for study days and time points refer to Flow Chart)
D: parameters to be determined at Visit 4 (end of trial examination)
2
Microscopic examination if erythrocytes, leukocytes, nitrite or protein in urinalysis are abnormal in urine
3
Estimated glomerular filtration rate according to CKD-EPI formula (R12-1392)
The tests listed in Table 5.2.3: 2 are exclusionary laboratory tests that may be repeated as 
required. The results will not be entered in the CRF/database and will not be reported in the 
CTR. Except for drug screening, it is planned to perform these tests during screening only. 
Drug screening will be performed at screening and prior to first dose in each treatment 
period.
Depending on development of COVID-19 pandemic, testing for SARC-CoV-2 infection will 
be done (e.g. PCR) prior to inclusion into the study and may be repeated as deemed 
appropriate.
Table 5.2.3: 2
Exclusionary laboratory tests
Functional lab group
Test name 
Drug screening (urine)
Amphetamine/MDA
Barbiturates
Benzodiazepine
Cannabis
Cocaine 
Methadone
Methamphetamines/MDMA/XTC
Opiates 
Phencyclidine
Tricyclic antidepressants
Infectious serology (blood)
Hepatitis B surface antigen (qualitative)
Hepatitis B core antibody (qualitative)
Hepatitis C antibodies (qualitative)
HIV-1 and HIV-2 antibody (qualitative)
To encourage compliance with alcoholic restrictions, a breath alcohol test (e.g. Alcotest®
 will be performed prior to each treatment period, and 
may be repeated at any time during the study at the discretion of an investigator or designee. 
The results will not be included in the CTR.
The laboratory tests listed in Tables 5.2.3: 1 and 5.2.3: 2 will be performed at
with the 
exception of drug screening tests. These tests will be performed at the trial site using
SureStepTM Multi-Drug Test (
).
Laboratory data will be transmitted electronically from the laboratory to the trial site.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 36 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
5.2.4
Electrocardiogram
Twelve-lead ECGs (I, II, III, aVR, aVL, aVF, V1 - V6) will be recorded using a 
computerised electrocardiograph (CardioSoft EKG System, 
) at the times provided in the Flow Chart.
To achieve a stable heart rate at rest and to assure high quality recordings, the site personnel 
will be instructed to assure a relaxed and quiet environment, so that all subjects are at 
complete rest.
All ECGs will be recorded for a 10 sec duration after subjects have rested for at least 5 min in 
a supine position. ECG assessment will always precede all other study procedures scheduled 
for the same time to avoid compromising ECG quality. 
All ECGs will be stored electronically on the Muse CV Cardiology System (
). Electrode placement will be performed according to the 
method of Wilson, Goldberger and Einthoven modified by Mason and Likar (hips and 
shoulders instead of ankles and wrists). 
All locally printed ECGs will be evaluated by the investigator or a designee. Abnormal 
findings will be reported as AEs (during the trial) or baseline conditions (at screening) if 
assessed to be clinically relevant by the investigator. Any ECG abnormalities will be 
carefully monitored and, if necessary, the subject will be removed from the trial and will 
receive the appropriate medical treatment. 
ECGs may be repeated for quality reasons (for instance, due to alternating current artefacts, 
muscle movements, or electrode dislocation) and the repeated ECG will be used for analysis. 
Additional (unscheduled) ECGs may be collected by the investigator for safety reasons. 
5.2.5
Other safety parameters
Not applicable.
5.2.6
Assessment of adverse events
5.2.6.1
Definitions of adverse events
Adverse event
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a medicinal product and which does not necessarily have 
to have a causal relationship with this treatment.
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
product, whether or not considered related to the medicinal product.
The following should also be recorded as an AE in the CRF and BI SAE form (if applicable):

Worsening of the underlying disease or of other pre-existing conditions 

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 37 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018

Changes in vital signs, ECG, physical examination, and laboratory test results, if they 
are judged clinically relevant by the investigator
If such abnormalities already pre-exist prior to trial inclusion, they will be considered as 
baseline conditions and should be collected in the eCRF only.
Serious adverse event
A serious adverse event (SAE) is defined as any AE which fulfils at least one of the 
following criteria:

Results in death 

Is life-threatening, which refers to an event in which the patient was at risk of death 
at the time of the event; it does not refer to an event that hypothetically might have 
caused death if more severe 

Requires inpatient hospitalisation  

Requires prolongation of existing hospitalisation

Results in persistent or significant disability or incapacity 

Is a congenital anomaly/birth defect 

Is deemed serious for any other reason if it is an important medical event when based 
upon appropriate medical judgment which may jeopardise the patient and may 
require medical or surgical intervention to prevent one of the other outcomes listed in 
the above definitions. Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalisation or development of dependency or 
abuse
AEs considered ‘Always Serious’
Cancers of new histology and exacerbations of existing cancer must be classified as a serious 
event regardless of the time since discontinuation of the trial medication and must be reported 
as described in 5.2.6.2, subsections ‘AE Collection’ and ‘AE reporting to sponsor and 
timelines’.
In accordance with the European Medicines Agency initiative on Important Medical Events, 
Boehringer Ingelheim has set up a list of further AEs, which, by their nature, can always be 
considered to be ‘serious’ even though they may not have met the criteria of an SAE as 
defined above.
The latest list of ‘Always Serious AEs’ can be found in the eDC system, an electronic data 
capture system which allows the entry of trial data at the trial site. These events should 
always be reported as SAEs as described above.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 38 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Adverse events of special interest
The term adverse events of special interest (AESI) relates to any specific AE that has been 
identified at the project level as being of particular concern for prospective safety monitoring 
and safety assessment within this trial, e.g. the potential for AEs based on knowledge from 
other compounds in the same class. AESIs need to be reported to the sponsor’s 
Pharmacovigilance Department within the same timeframe that applies to SAEs, please see 
Section 5.2.6.2.2.
The following are considered as AESIs:

Hepatic injury
A hepatic injury is defined by the following alterations of hepatic laboratory 
parameters: 
o
An elevation of AST (aspartate transaminase) and/or ALT (alanine 
transaminase) ≥3-fold ULN combined with an elevation of total bilirubin 
≥2-fold ULN measured in the same blood sample, or
o
Aminotransferase (ALT, and/or AST) elevations ≥10 fold ULN
These lab findings constitute a hepatic injury alert and the subjects showing these lab 
abnormalities need to be followed up according to the ‘DILI checklist’ provided in the 
ISF. In case of clinical symptoms of hepatic injury (icterus, unexplained 
encephalopathy, unexplained coagulopathy, right upper quadrant abdominal pain, 
etc.) without lab results (ALT, AST, total bilirubin) available, the Investigator should 
make sure that these parameters are analysed, if necessary in an unscheduled blood 
test. Should the results meet the criteria of hepatic injury alert, the procedures 
described in the DILI checklist should be followed.
Intensity (severity) of AEs
The intensity (severity) of the AE should be judged based on the following:
Mild:
Awareness of sign(s) or symptom(s) that is/are easily tolerated
Moderate:
Sufficient discomfort to cause interference with usual activity
Severe:
Incapacitating or causing inability to work or to perform usual activities
Causal relationship of AEs
Medical judgment should be used to determine the relationship, considering all relevant 
factors, including pattern of reaction, temporal relationship, de-challenge or re-challenge, 
confounding factors such as concomitant medication, concomitant diseases and relevant 
history.
Arguments that may suggest that there is a reasonable possibility of a causal relationship 
could be:

The event is consistent with the known pharmacology of the drug 

The event is known to be caused by or attributed to the drug class

A plausible time to onset of the event relative to the time of drug exposure

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 39 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018

Evidence that the event is reproducible when the drug is re-introduced

No medically sound alternative aetiologies that could explain the event (e.g. pre-
existing or concomitant diseases, or co-medications)

The event is typically drug-related and infrequent in the general population not 
exposed to drugs (e.g. Stevens-Johnson syndrome)

An indication of dose-response (i.e. greater effect size if the dose is increased, smaller 
effect size if dose is reduced)
Arguments that may suggest that there is no reasonable possibility of a causal relationship 
could be:

No plausible time to onset of the event relative to the time of drug exposure is evident 
(e.g. pre-treatment cases, diagnosis of cancer or chronic disease within days / weeks 
of drug administration; an allergic reaction weeks after discontinuation of the drug 
concerned)

Continuation of the event despite the withdrawal of the medication, taking into 
account the pharmacological properties of the compound (e.g. after 5 half-lives). Of 
note, this criterion may not be applicable to events whose time course is prolonged 
despite removing the original trigger

Additional arguments amongst those stated before, like alternative explanation (e.g. 
situations where other drugs or underlying diseases appear to provide a more likely 
explanation for the observed event than the drug concerned)

Disappearance of the event even though the trial drug treatment continues or remains 
unchanged
5.2.6.2
Adverse event collection and reporting
AE collection
Upon enrolment into a trial, the subject’s baseline condition is assessed (for instance, by 
documentation of medical history/concomitant diagnoses), and relevant changes from 
baseline are noted subsequently. 
Subjects will be required to report spontaneously any AEs as well as the time of onset, end
time, and intensity of these events. In addition, each subject will be regularly assessed by the
medical staff throughout the clinical trial and whenever the investigator deems necessary. As 
a minimum, subjects will be questioned for AEs (and concomitant therapies) at the time 
points indicated in the Flow Chart. Assessment will be made using non-specific questions 
such as ‘How do you feel?’. Specific questions will be asked wherever necessary in order to 
more precisely describe an AE.
A carefully written record of all AEs shall be kept by the investigator in charge of the trial. 
Records of AEs shall include data on the time of onset, end time, intensity of the event, and 
any treatment or action required for the event and its outcome.
The following must be collected and documented on the appropriate CRF(s) by the 
investigator:

From signing the informed consent onwards until an individual subject’s end of trial: 

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 40 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
o
All AEs (serious and non-serious) and all AESIs 
o
The only exception to this rule are AEs (serious and non-serious) and AESIs 
in Phase I trials in healthy volunteers, when subjects discontinue from the trial 
due to screening failures prior to administration of any trial medication. In 
these cases, the subjects’ data must be collected at trial site but will not be 
entered in the CRF or trial database and will not be reported in the CTR.

After the individual subject’s end of trial: 
o
The investigator does not need to actively monitor the subject for AEs but 
should only report any occurrence of cancer and related SAEs and related 
AESIs of which the investigator may become aware of by any means of 
communication, e.g. phone call. Those AEs should, however, not be reported 
in the CRF.
AE reporting to the sponsor and timelines
The Investigator must report SAEs, AESIs, and non-serious AEs which are relevant for the 
reported SAE or AESI, on the BI SAE form immediately (within 24 hours) to the sponsor’s 
unique entry point (country specific contact details will be provided in the ISF). The same 
timeline applies if follow-up information becomes available. In specific occasions the 
Investigator could inform the sponsor upfront via telephone. This does not replace the 
requirement to complete and send the BI SAE form. 
With receipt of any further information to these events, a follow-up SAE form has to be 
provided. For follow-up information, the same rules and timeline apply as for initial 
information.
Information required
All (S)AEs, including those persisting after the individual subject’s end of trial, must be 
followed up until they have resolved, have been sufficiently assessed as ‘chronic’ or ‘stable’, 
or no further information can be obtained.
5.3
DRUG CONCENTRATION MEASUREMENTS AND 
PHARMACOKINETICS
5.3.1
Assessment of pharmacokinetics
For the assessment of pharmacokinetics, blood samples will be collected at the time points 
indicated in the Flow Chart. The actual sampling times will be recorded and used for 
determination of pharmacokinetic parameters. 
5.3.2
Methods of sample collection
5.3.2.1
Blood sampling for pharmacokinetic analysis of BI 706321
For quantification of BI 706321 concentrations in plasma, 2.7 mL of blood will be drawn
from an antecubital or forearm vein into an K2-EDTA (dipotassium 

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 41 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
ethylenediaminetetraacetic acid)-anticoagulant blood drawing tube at the times indicated in 
the Flow Chart. Blood will be withdrawn by means of either an indwelling venous catheter or 
by venepuncture with a metal needle.
The EDTA-anticoagulated blood samples will be centrifuged for approximately 10 min at 
approximately 2000 g to 4000 g and at 4 to 8 °C. Two plasma aliquots will be obtained and 
stored in polypropylene tubes. The first aliquot should contain at least 0.5 mL of plasma. The 
second aliquot should contain the remaining plasma.
The process from blood collection until transfer of plasma aliquots into the freezer should be 
completed within 60 min, with interim storage of blood samples in ice water or on ice. The 
time each aliquot was placed in the freezer will be documented. Until transfer on dry ice to 
the analytical laboratory, the aliquots will be stored upright at approximately -20°C or below 
at the trial site. The second aliquot will be transferred to the analytical laboratory after the 
bioanalyst has acknowledged safe arrival of the first aliquot. At the analytical laboratory, the 
plasma samples will be stored at approximately -20°C or below until analysis.
At a minimum, the sample tube labels should list BI trial number, subject number, visit, 
planned sampling time, and the analyte ‘BI 706321’.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 42 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
5.4
BIOBANKING
Not applicable.
5.5
OTHER ASSESSMENTS
Not applicable.
5.6
APPROPRIATENESS OF MEASUREMENTS
All measurements performed during this trial are standard measurements and will be 
performed in order to monitor subjects’ safety and to determine pharmacokinetic parameters 
in an appropriate way. The scheduled measurements will allow monitoring of changes in vital 
signs, standard laboratory values, and ECG parameters that might occur as a result of 
administration of trial medication. The safety assessments are standard, are accepted for 
evaluation of safety and tolerability of an orally administered drug, and are widely used in 
clinical trials. The pharmacokinetic parameters and measurements outlined in Section 5.3 are 
generally used assessments of drug exposure. 

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 43 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
6.
INVESTIGATIONAL PLAN
6.1
VISIT SCHEDULE
Exact times of measurements outside the permitted time windows will be documented. The 
acceptable time windows for screening, the end of trial examination, and measurements and 
assessments scheduled to occur ‘before’ trial medication administrations are provided in the 
Flow Chart.
If not stated otherwise in the Flow Chart, the acceptable deviation from the scheduled time 
for the assessment of safety (e.g. vital signs, ECG, laboratory tests) will be ± 30 min.
If scheduled in the Flow Chart at the same time as a meal, blood sampling, vital signs, and 
12-lead ECG recordings have to be done first. Furthermore, if several measurements 
including venepuncture are scheduled for the same time, venepuncture should be the last of 
the measurements due to its inconvenience to the subject and possible influence on 
physiological parameters.
For planned blood sampling times, refer to the Flow Chart. While these nominal times should 
be adhered to as closely as possible, the actual sampling times will be recorded and used for 
the determination of pharmacokinetic parameters.
If a subject misses an appointment, it will be rescheduled if possible. The relevance of 
measurements outside the permitted time windows will be assessed no later than at the Report 
Planning Meeting.
6.2
DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS
6.2.1
Screening period
After having been informed about the trial, all subjects will provide written informed consent 
in accordance with GCP and local legislation prior to enrolment in the study.
For information regarding laboratory tests (including drug and virus screening), ECG, vital 
signs, and physical examination, refer to Sections 5.2.1 to 5.2.4.
6.2.2
Treatment periods
Each subject is expected to participate in 2 treatment periods (Day -3 to 9 in period 1 and Day 
-3 to 24 in period 2). At least 14 days will separate drug administration of BI 706321 in the 
first and second treatment period.
On Day 1 of each treatment period, study participants will be admitted to the trial site and 
kept under close medical surveillance for at least 24 h following drug administration in 
period 1 and for at least 46 hours following administration of BI 706321 in period 2. The 
subjects will then be allowed to leave the trial site after formal assessment and confirmation 
of their fitness. On all other study days, subjects will be treated in an ambulatory fashion.
For details on time points and procedures for collection of plasma samples for PK analysis, 
refer to Flow Chart and Section 5.3.2.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 44 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
The safety measurements performed during the treatment period are specified in Section 5.2
of this protocol and in the Flow Chart. For details on times of all other trial procedures, refer 
to the Flow Chart. AEs and concomitant therapy will be assessed continuously from 
screening until the end of trial examination.
6.2.3
Follow-up period and trial completion
For AE assessment, laboratory tests, recording of ECG and vital signs, and physical 
examination during the follow-up period, see Sections 5.2.1 to 5.2.6.
Subjects who discontinue treatment before the end of the planned treatment period should 
undergo the EoTrial Visit.
All abnormal values (including laboratory parameters) that are assessed as clinically relevant 
by the investigator will be monitored using the appropriate tests until a return to a medically 
acceptable level is achieved. (S)AEs persisting after a subject’s EoTrial Visit must be 
followed until they have resolved, have been sufficiently characterised, or no further 
information can be obtained. 

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 45 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
7.
STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
7.1
STATISTICAL DESIGN – MODEL
The main objective of this trial is to investigate the pharmacokinetics of BI 706321 in plasma 
when given as oral single dose together with multiple doses of itraconazole (Test, T) as 
compared to when given alone as oral single dose (Reference, R) on the basis of the primary 
and secondary pharmacokinetic endpoints, as listed in Sections 2.1.2 and 2.1.3. The trial is 
designed to allow intra-subject comparisons and will be evaluated statistically by use of a 
linear model for logarithmically transformed PK endpoints.
The assessment of safety is a further objective of this trial, and will be evaluated by 
descriptive statistics for the parameters specified in Section 2.2.2.2.
7.2
NULL AND ALTERNATIVE HYPOTHESES
The relative bioavailability of BI 706321 given in combination with itraconazole (T) 
compared with BI 706321 given alone (R) will be estimated by the ratios of the geometric 
means (T/R), and their corresponding 2-sided 90% confidence intervals (CIs) will be 
provided. This method corresponds to the two one-sided t-test procedure, each at the 5% 
significance level. Since the main focus is on estimation and not testing, a formal hypothesis 
test and associated acceptance range is not specified.
7.3
PLANNED ANALYSES
Analysis sets
Statistical analyses will be based on the following analysis sets:

Treated set (TS): The treated set includes all subjects who were treated with at least 
one dose of study drug. The treated set will be used for safety analyses.
Pharmacokinetic parameter analysis set (PKS): This set includes all subjects in the 
treated set (TS) who provide at least one PK endpoint that was defined as primary or 
secondary and was not excluded due to a protocol deviation relevant to the evaluation 
of PK or due to PK non-evaluability (as specified in the following subsection 
‘Pharmacokinetics’). Thus, a subject will be included in the PKS, even if he/she 
contributes only one PK parameter value for one period to the statistical assessment.
Descriptive and model based analyses of PK parameters will be based on the PKS.
Adherence to the protocol will be assessed by the trial team. Important protocol deviation 
(IPD) categories will be suggested in the IPD specification file prior to trial initiation, IPDs 
will be identified no later than in the Report Planning Meeting, and the IPD categories will be 
updated as needed.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 46 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Pharmacokinetics
The pharmacokinetic parameters listed in Section 2.1 for BI 706321 will be calculated 
according to the sponsor’s SOP ‘Standards and processes for analyses performed within 
Clinical Pharmacokinetics/ Pharmacodynamics’ (001-MCS-36-472). 
Plasma concentration data and parameters of a subject will be included in the statistical 
pharmacokinetic (PK) analyses if they are not flagged for exclusion due to a protocol 
deviation relevant to the evaluation of PK (to be decided no later than in the Report Planning 
Meeting) or due to PK non-evaluability (as revealed during data analysis, based on the 
criteria specified below). Exclusion of a subject’s data will be documented in the CTR.
Relevant protocol deviations may be

Incorrect trial medication taken, i.e. the subject received at least one dose of trial
medication the subject was not assigned to

Incorrect dose of trial medication taken

Use of restricted medications
Plasma concentrations and/or parameters of a subject will be considered as non-evaluable, if 
for example

The subject experienced emesis that occurred at or before two times median tmax of 
the respective treatment (median tmax is to be determined excluding the subjects 
experiencing emesis)

A predose concentration of BI 706321 is >5% Cmax value of that subject in the 
respective treatment period

Missing samples/concentration data at important phases of PK disposition curve
Plasma concentration data and parameters of a subject which is flagged for exclusion will be 
reported with its individual values but will not be included in the statistical analyses. 
Descriptive and inferential statistics of PK parameters will be based on the PKS.
Only concentration values within the validated concentration range and actual sampling times 
will be used for the calculation of pharmacokinetic parameters. Concentrations used in the 
pharmacokinetic calculations will be in the same format provided in the bioanalytical report, 
(that is, to the same number of decimal places provided in the bioanalytical report). 
7.3.1
Primary endpoint analyses
Primary analyses
The statistical model used for the analysis of the primary endpoints will be an analysis of 
variance (ANOVA) model on the logarithmic scale. That is, the PK endpoints will be log-
transformed (natural logarithm) prior to fitting the ANOVA model. This model will include 
effects accounting for the following sources of variation: subjects and treatment. The effect 
'subjects' will be considered as random, whereas 'treatment' will be considered as fixed. The 
model is described by the following equation:
ykm = + sm + k + ekm, where

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 47 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
ykm = logarithm of response measured on subject m receiving treatment k,
= the overall mean,
sm = the effect associated with the mth subject, m = 1, 2, ..., n
k = the kth treatment effect, k = 1, 2
ekm = the random error associated with the mth subject who received treatment k
where sm ~ N0,σB
2 i.i.d., ekm ~ N0,σW
2  i.i.d. and sm, ekm are independent random 
variables.
Point estimates for the ratios of the geometric means (test/reference) for the primary 
endpoints (see Section 2.1) and their two-sided 90% confidence intervals (CIs) will be 
provided.
For each endpoint, the difference between the expected means for log(T)-log(R) will be 
estimated by the difference in the corresponding adjusted means (Least Squares Means).
Additionally their two-sided 90% confidence intervals will be calculated based on the 
residual error from the ANOVA and quantiles from the t-distribution. These quantities will 
then be back-transformed to the original scale to provide the point estimate and 90% CIs for 
each endpoint.
Further exploratory analyses
The same statistical model as stated above will be repeated for the primary endpoints but with 
‘subjects’ considered as fixed effects.
In addition to the model based approach all parameters will be calculated and analysed 
descriptively.
7.3.2
Secondary endpoint analyses
The secondary endpoints (refer to Section 2.1.3) will be calculated according to the BI SOP 
001-MCS-36-472 and will be assessed statistically using the same methods as described for 
the primary endpoints.
7.3.4
Safety analyses
Safety will be analysed based on the assessments described in Section 2.2.2.2. All treated 
subjects (TS, refer to Section 7.2) will be included in the safety analysis. Safety analyses will 
be descriptive in nature and based on BI standards. No hypothesis testing is planned.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 48 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
For all analyses, the treatment actually administered (= treatment at onset) to the subject will 
be used (any deviations from treatment will be discussed in the minutes of the Report 
Planning Meeting).
Treatments will be compared in a descriptive way. Tabulations of frequencies/proportions 
will be used to evaluate categorical (qualitative) data, and tabulations of descriptive statistics 
will be used to analyse continuous (quantitative) data.
Measurements (such as ECG, vital signs, or laboratory parameters) or AEs will be assigned to 
treatments (see Section 4.1) based on the actual treatment at the planned time of the 
measurement or on the recorded time of AE onset (concept of treatment emergent AEs).
Therefore, measurements planned or AEs recorded prior to first intake of trial medication will 
be assigned to the screening period, those between first trial medication intake and end of 
REP (see Section 1.2.3) will be assigned to the treatment period. Events occurring after the 
REP but prior to next intake or end of trial termination date will be assigned to ’follow-up’. 
In case of two or more treatments, the follow-up will be summarized according to the 
previous treatment. These assignments including the corresponding time intervals will be 
defined in detail in the TSAP. Note that AEs occurring after the last per protocol contact but 
entered before final database lock will be reported to Pharmacovigilance only and will not be 
captured in the trial database.
Additionally, further treatment intervals (analysing treatments) may be defined in the TSAP 
in order to provide summary statistics for time intervals, such as combined treatments, on-
treatment totals, or periods without treatment effects (such as screening and follow-up 
intervals).
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). Frequency, severity, and causal relationship of AEs will be tabulated by 
treatment, system organ class, and preferred term. SAEs, AESIs (see Section 5.2.6.1), and 
other significant AEs (according to ICH E3) will be listed separately.
Previous and concomitant therapies will be presented per treatment group without 
consideration of time intervals and treatment periods.
Laboratory data will be compared to their reference ranges. Values outside the reference 
range as well as values defined as possibly clinically significant will be highlighted in the 
listings. Additionally, differences from baseline will be evaluated.
Vital signs or other safety-relevant data will be assessed with regard to possible on-treatment 
changes from baseline.
7.4
INTERIM ANALYSES
No interim analysis is planned.
7.5
HANDLING OF MISSING DATA
7.5.1
Safety
It is not planned to impute missing values for safety parameters.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 49 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
7.5.2
Pharmacokinetics
Handling of missing PK data will be performed according to the relevant Corporate 
Procedure (001-MCS-36-472).
PK parameters that cannot be reasonably calculated based on the available drug 
concentration-time data will not be imputed.
7.6
RANDOMISATION
In this trial subjects receive all treatments in the same order, thus no randomisation for the 
treatment assignment is performed (see also Section 4.1.3).
7.7
DETERMINATION OF SAMPLE SIZE
It is planned to enter a total of 14 subjects in the trial (accounting for up to 2 dropouts or non 
PK evaluable subjects), because this sample size is considered sufficient to achieve the aims 
of this exploratory trial. With this sample size, the following precision in estimating the ratio 
of geometric means (test/reference) can be expected with 95% probability. Precision is 
defined as the ratio of upper confidence interval (CI) limit to the estimate of ratio of 
geometric means. Note that the precision is independent of the actual ratio of geometric 
means.
The observed coefficient of variation (gCV%) after a single oral dose of BI 706321
preliminary results) in trial 1425-0001 was roughly 
The reported variability originated from a parallel group estimates total variability. However, 
for this trial as a crossover trial intra-individual gCV is needed. 
 
For various assumptions around the gCV of 
 Table 7.7: 1 provides an overview of the 
achievable precision for estimating the ratio of geometric means (test/reference). For 
illustrative purposes, the expected 90% confidence intervals are displayed for different values 
of the ratios T/R of geometric means.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 50 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Table 7.7: 1
Precision that can be expected with 95% probability and illustrative 
two-sided 90% confidence intervals around the ratios of geometric 
means (T/R) for different gCVs in a two-period fixed sequence trial 
(N=12)
Precision upper 
CI limit / relative 
BA estimate
Ratio [%]*
Lower CI limit
[%]
Upper CI limit
[%]
20.0
1.21
100
82.35
121.43
20.0
1.21
150
123.53
182.15
20.0
1.21
200
164.70
242.86
25.0
1.27
100
78.55
127.31
25.0
1.27
150
117.83
190.96
25.0
1.27
200
157.10
254.61
30.0
1.33
100
74.99
133.36
30.0
1.33
150
112.48
200.03
30.0
1.33
200
149.98
266.71
*Ratio of geometric means (test/reference) for a PK endpoint is defined by exp(T)/exp(R).
The expected 90% confidence interval limits in the table were derived by
CI limit, = exp(ln(θ) ± ω),
with θ being the ratio (T/R) on original scale and ω the distance from the estimate θ to either 
confidence interval limit on the log-scale, which was obtained from the achievable precision 
on the original scale.
The calculation was performed as described by Julious [R11-5230] using R Version 3.6.1.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 51 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
8.
INFORMED CONSENT, TRIAL RECORDS, DATA 
PROTECTION, PUBLICATION POLICY, AND
ADMINISTRATIVE STRUCTURE
The trial will be carried out in compliance with the protocol, the ethical principles laid down 
in the Declaration of Helsinki, in accordance with the ICH Harmonized Guideline for Good 
Clinical Practice (GCP), relevant BI Standard Operating Procedures (SOPs), the EU 
regulation 536/2014, and other relevant regulations. Investigators and site staff must adhere 
to these principles.
Standard medical care (prophylactic, diagnostic, and therapeutic procedures) remains the 
responsibility of the subject’s treating physician.
The investigator will inform the sponsor immediately of any urgent safety measures taken to 
protect the trial subjects against any immediate hazard, as well as of any serious breaches of 
the protocol or of ICH GCP.
Within 1 year after trial termination the Sponsor will submit a summary of the CTR covering 
all relevant results of the trial to the Competent Authority and to the Independent Ethics 
Committee.
The Boehringer Ingelheim transparency and publication policy can be found on the following 
web page: trials.boehringer-ingelheim.com. The rights of the investigator and of the sponsor 
with regard to publication of the results of this trial are described in the investigator contract.
As a general rule, no trial results should be published prior to archiving of the CTR.
The terms and conditions of the insurance coverage are made available to the investigator and 
the  subjects, and are stored in the ISF.
8.1
TRIAL APPROVAL, SUBJECT INFORMATION, INFORMED CONSENT
This trial will be initiated only after all required legal documentation has been reviewed and 
approved by the respective Institutional Review Board (IRB / Independent Ethics Committee 
(IEC and competent authority (CA) according to national and international regulations. The 
same applies for the implementation of changes introduced by amendments.
Prior to a subject’s participation in the trial, written informed consent must be obtained from 
each subject (or the subject’s legally accepted representative) according to ICH-GCP and to 
the regulatory and legal requirements of the participating country. Each signature must be 
personally dated by each signatory and the informed consent and any additional subject-
information form retained by the investigator as part of the trial records. A signed copy of the 
informed consent and any additional subject information must be given to each subject or the 
subject’s legally accepted representative.
The subject must be given sufficient time to consider participation in the trial. The 
investigator or delegate obtains written consent of the subject’s own free will with the 
informed consent form after confirming that the subject understands the contents. The 
investigator or 
 delegate must sign (or place a seal on) and date the informed consent form. 
If a trial collaborator has given a supplementary explanation, the trial collaborator also signs 
(or places a seal on) and dates the informed consent.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 52 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Re-consenting may become necessary when new relevant information becomes available and 
should be conducted according to the sponsor’s instructions.
The consent and re-consenting process should be properly documented in the source 
documentation.
8.2
DATA QUALITY ASSURANCE
A risk-based approach is used for trial quality management. It is initiated by the assessment 
of critical data and processes for trial subject protection and reliability of the results as well as 
identification and assessment of associated risks. An Integrated Quality and Risk 
Management Plan documents the rationale and strategies for risk management during trial 
conduct including monitoring approaches, vendor management and other processes focusing 
on areas of greatest risk. 
Continuous risk review and assessment may lead to adjustments in trial conduct, trial design 
or monitoring approaches. 
A quality assurance audit/inspection of this trial may be conducted by the sponsor, sponsor’s 
designees, or by IRB / IEC or by regulatory authorities. The quality assurance auditor will 
have access to all medical records, the investigator’s trial-related files and correspondence, 
and the informed consent documentation of this clinical trial..
8.3
RECORDS
CRFs for individual subjects will be provided by the sponsor. For drug accountability, refer 
to Section 4.1.8.
8.3.1
Source documents
In accordance with regulatory requirements, the investigator should prepare and maintain 
adequate and accurate source documents and trial records for each trial subject that include 
all observations and other data pertinent to the investigation. Source data as well as reported 
data should follow the ‘ALCOA principles’ and be attributable, legible, contemporaneous, 
original, and accurate. Changes to the data should be traceable (audit trail).
Data reported on the CRF must be consistent with the source data or the discrepancies must 
be explained.
Before providing any copy of subjects’ source documents to the sponsor, the investigator 
must ensure that all subject identifiers (e.g., subject’s name, initials, address, phone number, 
and social security number) have properly been removed or redacted to ensure subject 
confidentiality.
If the subject is not compliant with the protocol, any corrective action (e.g. re-training) must 
be documented in the subject file.
For the CRF, data must be derived from source documents, for example:

Subject identification: sex, year of birth (in accordance with local laws and 
regulations)

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 53 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018

Subject participation in the trial (substance, trial number, subject number, date subject 
was informed)

Dates of subject’s visits, including dispensing of trial medication

Medical history (including trial indication and concomitant diseases, if applicable)

Medication history

AEs and outcome events (onset date [mandatory], and end date [if available])

SAEs (onset date [mandatory], and end date [if available])

Concomitant therapy (start date, changes)

Originals or copies of laboratory results and other imaging or testing results, with 
proper documented medical evaluation (in validated electronic format, if available)

ECG results (original or copies of printouts)

Completion of subject’s participation in the trial (end date; in case of premature 
discontinuation, document the reason for it, if known)

Prior to allocation of a subject to a treatment into a clinical trial, there must be 
documented evidence in the source data (e.g. medical records) that the trial participant 
meets all inclusion criteria and does not meet any exclusion criteria. The absence of 
records (either medical records, verbal documented feedback of the subject or testing 
conducted specific for a protocol) to support inclusion/exclusion criteria does not 
make the subject eligible for the clinical trial.
8.3.2
Direct access to source data and documents
The investigator /institution will allow site trial-related monitoring, audits, IRB / IEC review 
and regulatory inspections. Direct access must be provided to the CRF and all source 
documents/data, including progress notes, copies of laboratory and medical test results, which 
must be available at all times for review by the Clinical Research Associate, auditor and 
regulatory inspector (e.g. FDA). They may review all CRFs and informed consents. The 
accuracy of the data will be verified by direct comparison with the source documents 
described in Section 8.3.1. The sponsor will also monitor compliance with the protocol and 
GCP.
8.3.3
Storage period of records
Trial site:
The trial site(s) must retain the source and essential documents (including ISF) according to 
contract or the local requirements valid at the time of the end of the trial (whatever is longer).
Sponsor:
The sponsor must retain the essential documents according to the sponsor’s SOPs.
8.4
EXPEDITED REPORTING OF ADVERSE EVENTS
BI is responsible to fulfil their legal and regulatory reporting obligation in accordance with 
regulatory requirements.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 54 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
8.5
STATEMENT OF CONFIDENTIALITY AND SUBJECT PRIVACY
Individual subject data obtained as a result of this trial is considered confidential and 
disclosure to third parties is prohibited with the exceptions noted in Section 8.7. 
Data protection and data security measures are implemented for the collection, storage and 
processing of patient data in accordance with the principles 6 and 12 of the WHO GCP 
handbook.
Personalised treatment data may be given to the subject’s personal physician or to other 
appropriate medical personnel responsible for the subject’s welfare. Data generated at the site 
as a result of the trial need to be available for inspection on request by the participating 
physicians, the sponsor’s representatives, by the IRB / IEC and the regulatory authorities.
8.5.1
Collection, storage and future use of biological samples and corresponding 
data
Measures are in place to comply with the applicable rules for the collection, storage and 
future use of biological samples and clinical data, in particular

Sample and data usage has to be in accordance with the informed consent

The BI-internal or external facilities storing biological samples from clinical trial 
participants are qualified for the storage of biological samples collected in clinical 
trials.

An appropriate sample and data management system, incl. audit trail for clinical data 
and samples to identify and destroy such samples according to ICF is in place

A fit for the purpose documentation (e.g. biomarker proposal, analysis plan and 
report) ensures compliant usage

A fit for purpose approach will be used for assay/equipment validation depending on 
the intended use of the data
Samples and/or data may be transferred to third parties and other countries as specified in the 
ICF.
8.6
TRIAL MILESTONES
The start of the trial is defined as the date of the enrolment of the first subject in the trial.
The end of the trial (‘Last Subject Completed’) is defined as the ‘date of the last visit of the 
last subject in whole trial’.
Early termination of the trial is defined as the premature termination of the trial for any 
reason before the end of the trial as specified in this protocol.
Temporary halt of the trial is defined as any unplanned interruption of the trial by the 
sponsor with the intention to resume it.
Suspension of the trial is defined as an interruption of the trial based on a Health Authority 
request.
The EC/competent authority in each participating EU member state will be notified about the 
trial milestones according to the laws of each member state. 

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 55 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
A final report of the clinical trial data will be written only after all subjects have completed 
the trial in all countries (EU or non-EU), so that all data can be incorporated and considered 
in the report.
The sponsor will submit to the EU database a summary of the final trial results within one 
year from the end of a clinical trial as a whole, regardless of the country of the last patient 
(EU or non-EU).
8.7
ADMINISTRATIVE STRUCTURE OF THE TRIAL
The trial is sponsored by Boehringer Ingelheim.
The trial will be conducted at
 under the supervision of the Principal Investigator. Tasks and responsibilities are 
defined in a contract. Relevant documentation on the participating (Principal) Investigators 
(e.g. their curricula vitae) will be filed in the ISF.
BI has appointed a Clinical Trial Leader, responsible for coordinating all required trial 
activities, in order to 

Manage the trial in accordance with applicable regulations and internal SOPs

Direct the clinical trial team in the preparation, conduct, and reporting of the trial

ensure appropriate training and information of local clinical monitors (CML), Clinical 
Research Associates, and investigators of participating trial sites
The trial medication will be provided by the 
(BI 706321) or will be obtained by the clinical trial site from 
public pharmacy (itraconazole).
Safety laboratory tests will be performed by the local laboratory of the trial site
.
Analyses of BI 706321 
 concentrations in plasma will be performed at
 
.
On-site monitoring will be performed by BI or a contract research organisation appointed by 
BI.
Data management and statistical evaluation will be done by BI or a contract research 
organisation according to BI SOPs.
Tasks and functions assigned in order to organise, manage, and evaluate the trial are defined 
according to BI SOPs. A list of responsible persons and relevant local information can be 
found in the ISF.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 56 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
9.
REFERENCES 
9.1
PUBLISHED REFERENCES
P07-13746
Heeswijk RPG van, Bourbeau M, Campbell P, Seguin I, Chauhan BM, 
Foster BC, Cameron DW. Time-dependent interaction between 
lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 46, 758-767 
(2006).
P15-06298
Ministry of Health, Labour and Welfare. Drug interaction guideline for 
drug development and labeling recommendations (draft). 
http://www.solvobiotech.com/documents/Japanese_DDI_guideline_(draft)
_2014Jan.pdf (access date: 22 June 2015); Ministry of Health, Labour and 
Welfare; 2014.
P15-06991
European Medicines Agency (EMA). Committee for Human Medicinal 
Products (CHMP): guideline on the investigation of drug interactions (21 
June 2012, CPMP/EWP/560/95/rev. 1 corr. 2). 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guid
eline/2012/0 7/WC500129606.pdf (access date: 8 July 2015); London: 
European Medicines Agency (EMA); 2012.
R01-0516
Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in 
patients receiving the systemic antimycotics ketoconazole or itraconazole. 
Clin Pharmacol Ther 1994. 55(5):481-485. 
R08-1652
Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C. 
Mechanism of ritonavir changes in methadone pharmacokinetics and 
pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein 
activities. Clinical Pharmacology and Therapeutics, advance online 
publication 9 July 2008, doi:10.1038/clpt.2008.102 Clin Pharmacol Ther 
2008.
R10-1102
Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson 
WL, Isoherranen N. Contribution of itraconazole metabolites to inhibition 
of CYP3A4 in vivo. Clin Pharmacol Ther 2008; 83(1):77-85.
R11-5230
Julious SA. Sample sizes for clinical trials. Boca Raton: Taylor & Francis 
Group; 2010.
R12-1392
Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, 
Kusek JW, Eggers P, Lente F van, Greene T, Coresh J, Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI). A new equation to 
estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604-612.
R15-3252
Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal 
clearance of digoxin. Ther Drug Monit 1997. 19(6):609-613.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 57 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
R17-3742
Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman 
RH, et al. Food interaction and steady-state pharmacokinetics of 
itraconazole oral solution in healthy volunteers (2017). Pharmacotherapy 
1998 ; 18(2) ; 295-301.
R17-3743
Willems L, Geest R van der, Beule K de. Itraconazole oral solution and 
intravenous formulations: a review of pharmacokinetics and 
pharmacodynamics. J Clin Pharm Ther 2001; 26:159-169.
R17-3744
Liu L, Bello A, Dresser MJ, Heald D, Komjathy SF, O'Mara E, et al. Best 
practices for the use of itraconazole as a replacement for ketoconazole in 
drug-drug interaction studies. J Clin Pharmacol 2016. 56(2):143-151.
R18-0241
Guidance for industry: clinical drug interaction studies - study design, data
analysis, and clinical implications (draft guidance, this guidance document 
is being distributed for comment purposes only) (October 2017, clinical 
pharmacology). 
https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf (access 
date: 19 January 2018); Silver Spring: U.S. Department of Health and 
Human Services, Food and Drug Administration, Center for Drug 
Evaluation and Research (CDER) 2017. 
R18-2643
Sporanox 10 mg/ml oral solution (Janssen-Cilag) (summary of product 
characteristics, updated 01-Mar-2018). https://www.medicines.org.uk/
emc/product/1522/smpc/print (access date: 14 August 2018); 2018.
R20-2709
Sempera Liquid 10 mg/ml, Loesung zum Einnehmen (Janssen-Cilag) 
(Fachinformation, Stand der Information: May 2020). 2020.
R94-1529
Chow SC, Liu JP, editors. Design and analysis of bioavailability and 
bioequivalence studies. New York: Marcel Dekker Inc., 1992.
9.2
UNPUBLISHED REFERENCES
001-MCS-36-472 Standards and processes for analyses performed within Clinical 
Pharmacokinetics/Pharmacodynamics. Current version
c02336088
. Relative bioavailability of a 
single oral dose of BI 691751 when administered alone or in combination 
with multiple oral doses of itraconazole in healthy male subjects (an open-
label, randomised, two-period, two-sequence crossover study). Clinical 
Trial Report. 1334.10. 09 January 2015.
c03355329
. Relative bioavailability of a 
single oral dose of BI 425809 when administered alone or in combination 
with multiple oral doses of itraconazole in healthy male subjects (an open-
label, two-period, fixed-sequence trial). Clinical Trial Report. 1346.10. 
03 December 2015. 

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 58 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
c08928447
 Effect of multiple doses of 
itraconazole on the pharmacokinetics of a single oral dose of BI 1026706 
in healthy male subjects (an open-label, randomised, two-period, two-
sequence crossover study). Clinical Trial Report. 1320.20. 29 September 
2016.
c26475781
. Investigator's Brochure BI 706321 
 Current 
Version.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 59 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
10.
APPENDICES
Not applicable.

Boehringer Ingelheim
01 Feb 2021
BI Trial No.: 1425-0010
c32737758-02
Trial Protocol
Page 60 of 60
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
11.
DESCRIPTION OF GLOBAL AMENDMENT(S)
11.1
GLOBAL AMENDMENT 1
Date of amendment
01 February 2021
EudraCT number
2020-004388-22
BI Trial number
1425-0010
BI Investigational Medicinal 
Product
BI 706321
Title of protocol
Effect of itraconazole on the pharmacokinetics of a 
single oral dose of BI 706321 in healthy male 
subjects (an open-label, two-period fixed sequence 
design study)
To be implemented only after approval of the IRB / IEC / Competent 
Authorities
To be implemented immediately in order to eliminate hazard – IRB / IEC / 
Competent Authority to be notified of change with request for approval
Can be implemented without IRB / IEC / Competent Authority approval as 
changes involve logistical or administrative aspects only
Section to be changed
5.3.2.1
Description of change
Changed handling of PK blood samples taken for 
analysis of BI 706321 (allowed time period between 
sample withdrawal and freezing shortened; interim 
storage of blood samples on ice instead of at room 
temperature)
Rationale for change
Unknown stability data in case of further use of 
samples (e.g. metabolite determination)





$33529$/6,*1$785(3$*(

'RFXPHQW1XPEHU

7HFKQLFDO9HUVLRQ1XPEHU

'RFXPHQW1DPH





7LWOH






6LJQDWXUHVREWDLQHGHOHFWURQLFDOO\

0HDQLQJRI6LJQDWXUH
6LJQHGE\
'DWH6LJQHG



















































F

FOLQLFDOWULDOSURWRFROYHUVLRQ
(IIHFWRILWUDFRQD]ROHRQWKHSKDUPDFRNLQHWLFVRIDVLQJOHRUDOGRVHRI%,LQ
KHDOWK\PDOHVXEMHFWVDQRSHQODEHOWZRSHULRGIL[HGVHTXHQFHGHVLJQVWXG\
$XWKRU&OLQLFDO7ULDO/HDGHU
)HE&(7
$SSURYDO7HDP0HPEHU0HGLFLQH
)HE&(7
$XWKRU7ULDO6WDWLVWLFLDQ
)HE&(7
9HULILFDWLRQ3DSHU6LJQDWXUH
&RPSOHWLRQ
)HE&(7
$SSURYDO&OLQLFDO3KDUPDFRNLQHWLFV
)HE&(7
$SSURYDO7KHUDSHXWLF$UHD
)HE&(7

%RHKULQJHU,QJHOKHLP
3DJHRI
'RFXPHQW1XPEHU
 7HFKQLFDO9HUVLRQ1XPEHU



&RQWLQXHG6LJQDWXUHVREWDLQHGHOHFWURQLFDOO\

0HDQLQJRI6LJQDWXUH
6LJQHGE\
'DWH6LJQHG






















































































F
